Hirsch教授：我是来自科罗拉多大学的Fred Hirsch，代表国际肺癌研究协会（IASLC）。由我在日内瓦会议现场报导正在召开的由IASLC和ESMO合办的第五届欧洲肺癌大会。作为一项重要的肺癌会议，本次会议带来了大量新知识。且涵盖许多领域。在4月16日上午的还有一个“免疫治疗是NSCLC的一线治疗选择吗？（Is immunotherapy a first-line treatment for NSCLC?）”的辩论环节。希望这次会议的成果也可以在中国和亚洲其他地区得以传播。

　　肺癌是一个全球问题，不仅存在于美国或是欧洲，因此汇集世界各地新的科学进展十分重要。所以我们希望这次会议不仅限于欧洲范围内，也可以为亚洲包括中国和其他国家的同侪带来新的知识。这无疑是IASLC等全球性肺癌协会的共同目标。

　　原文：Hello， my name is Dr. Fred Hirsch from the University of Colorado. I also represent the international association for the study of lung cancer. I’m reporting from the European Lung Cancer meeting in Geneva， which is a joint venture between IASLC and ESMO. This lung cancer meeting is important， and brings a lot of new knowledge to the world. Among many other things， there are a lot of immunotherapy discussions， and hopefully the results from the meeting here can also be disseminated in China and the rest of Asia.

　　Lung cancer is a global phenomenon; it is not an American phenomenon; it is not a European phenomenon. It is important that the new scientific advancements come through in all parts of the world. So it is our hope that this meeting， even if it is a European meeting， can bring new knowledge to our Asian colleagues in China and other countries.  That is certainly also the goal for a global lung cancer association like IASLC.